Mucosal IgA specificity and neutralization
. | . | CCR5 binding activity by serum Ig* . | . | CCR5 binding activity by mucosal IgA* . | . | Binding specificity on CCR5 peptides covering extra-membrane region of CCR5 by mucosal IgA . | . | . | . | . | . | SOS pseudovirus neutralization by mucosal IgA† . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESN no. . | Age, y/sex . | IgG . | IgA . | Genital . | Salivary . | aa 14-34 . | aa 90-103 . | aa 167-178 . | aa 178-197 . | aa 260-274 . | Control peptide‡ . | HIV-R5 genital/salivary . | VSV-G genital/salivary . | ||||||||
| 53 | 22/M | 6780 | 6 420 | 9850 | 7100 | − | + | − | − | − | − | 2.3/0.8 | >40/>40 | ||||||||
| 55 | 38/M | 6550 | 5 340 | 8250 | 8100 | − | + | − | − | − | − | 1.1/1.5 | >40/>40 | ||||||||
| 34 | 43/F | 8020 | 300 | 250 | 250 | − | − | − | − | − | − | >40§ />40§ | >40§ />40§ | ||||||||
| 31 | 29/M | 8500 | 4 800 | 6200 | 7080 | − | + | − | − | − | − | 2.8/5.8 | >40/>40 | ||||||||
| 32 | 41/M | 6570 | 8 010 | 9650 | 8320 | − | + | − | − | − | − | 3.7/2.8 | >40/>40 | ||||||||
| 112 | 37/F | 4650 | 5 250 | 6430 | 6660 | − | + | − | − | − | − | 0.9/1.5 | >40/>40 | ||||||||
| 108 | 32/F | 8020 | 8 840 | 260 | 280 | − | − | − | − | − | − | >40§ />40§ | >40§ />40§ | ||||||||
| 109 | 35/F | 9150 | 11 500 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ||||||||
| 111 | 45/M | 6250 | 4 800 | 8010 | 6300 | − | + | − | − | − | − | 2.2/2.6 | >40§ />40§ | ||||||||
| HD pool | Range, 25-45/5M + 5F | 250 | 250 | 310 | 295 | − | − | − | − | − | − | >40§ />40§ | >40§ />40§ | ||||||||
. | . | CCR5 binding activity by serum Ig* . | . | CCR5 binding activity by mucosal IgA* . | . | Binding specificity on CCR5 peptides covering extra-membrane region of CCR5 by mucosal IgA . | . | . | . | . | . | SOS pseudovirus neutralization by mucosal IgA† . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESN no. . | Age, y/sex . | IgG . | IgA . | Genital . | Salivary . | aa 14-34 . | aa 90-103 . | aa 167-178 . | aa 178-197 . | aa 260-274 . | Control peptide‡ . | HIV-R5 genital/salivary . | VSV-G genital/salivary . | ||||||||
| 53 | 22/M | 6780 | 6 420 | 9850 | 7100 | − | + | − | − | − | − | 2.3/0.8 | >40/>40 | ||||||||
| 55 | 38/M | 6550 | 5 340 | 8250 | 8100 | − | + | − | − | − | − | 1.1/1.5 | >40/>40 | ||||||||
| 34 | 43/F | 8020 | 300 | 250 | 250 | − | − | − | − | − | − | >40§ />40§ | >40§ />40§ | ||||||||
| 31 | 29/M | 8500 | 4 800 | 6200 | 7080 | − | + | − | − | − | − | 2.8/5.8 | >40/>40 | ||||||||
| 32 | 41/M | 6570 | 8 010 | 9650 | 8320 | − | + | − | − | − | − | 3.7/2.8 | >40/>40 | ||||||||
| 112 | 37/F | 4650 | 5 250 | 6430 | 6660 | − | + | − | − | − | − | 0.9/1.5 | >40/>40 | ||||||||
| 108 | 32/F | 8020 | 8 840 | 260 | 280 | − | − | − | − | − | − | >40§ />40§ | >40§ />40§ | ||||||||
| 109 | 35/F | 9150 | 11 500 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ||||||||
| 111 | 45/M | 6250 | 4 800 | 8010 | 6300 | − | + | − | − | − | − | 2.2/2.6 | >40§ />40§ | ||||||||
| HD pool | Range, 25-45/5M + 5F | 250 | 250 | 310 | 295 | − | − | − | − | − | − | >40§ />40§ | >40§ />40§ | ||||||||
ND indicates not determined.
The values are expressed as counts per minute (CPM).
The values are expressed as IC50, which correspond to 90-103-specific IgA concentration (ng/mL) yielding 50% of HIV inhibition.
Sequence of control peptide to VQGEESNDK.
This value corresponds to IC50 obtained with total mucosal IgA instead of CCR5-specific IgA.